TY - JOUR ID - 13882 TI - Therapeutic effects of HESA-A (a herbal-marine compound) in acute organophosphorus pesticide poisoning JO - Avicenna Journal of Phytomedicine JA - AJP LA - en SN - 2228-7930 AU - Mousavi, Seyed Reza AU - Moshiri, Mohammad AU - Darchini-Maragheh, Emadodin AU - Ghasempouri, Seyed Khosro AU - Dadpour, Bita AU - Sardar Antighechi, Faezeh AU - Balali-Mood, Mahdi AD - Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Cutaneous Leishmaniasis Research Center, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Forensic Medicine and Toxicology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. AD - Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran. Y1 - 2020 PY - 2020 VL - 10 IS - 3 SP - 235 EP - 242 KW - Organophosphorus pesticides KW - Poisoning KW - Clinical trial KW - HESA-A DO - 10.22038/ajp.2019.13882 N2 - Objective: Organophosphorus compounds (OPs) are common causes of poisonings. Atropine and oximes are pharmacological antidotes of OPs. However, because of their adverse effects and insufficient performance, several other compounds have been evaluated as adjuvant therapy. HESA-A is a herbal-marine drug that contains material from Carum carvi (Persian cumin), Penaeus latisculatus (king prawn), and Apium graveolens (celery) with anti-inflammatory and antioxidants properties, which has shown useful effects as adjuvant therapy on some diseases. We have evaluated the effect of HESA-A on 69 moderate to severe acute OPs poisoned patients (44 HESA-A treated and 25 controls) as an adjuvant drug. Materials and Methods: Two randomized age and sex matched groups of OPs poisoned patients were treated in Medical Toxicology Center of Imam Reza hospital, Mashhad, by conventional therapy with or without HESA-A (50 mg/kg/day orally). The evaluation criteria were total administrated doses of atropine and pralidoxime, intensive care unit (ICU) admission rate, mechanical respiration need, number of hospitalization days and mortality. Results: There were no significant differences between the morbidity and mortality rate criteria of the two groups; moreover, we did not observe significant adverse effects for HESA-A. Conclusion: HESA-A did not reduce morbidity and mortality of OPs poisoning and did not induce any major side effect in the patients. UR - https://ajp.mums.ac.ir/article_13882.html L1 - https://ajp.mums.ac.ir/article_13882_a1bc5625f7b687a72c161212e5ae2b42.pdf ER -